Clinical impact of melatonin on breast cancer patients undergoing chemotherapy; effects on cognition, sleep and depressive symptoms: A randomized, double-blind, placebo-controlled trial.
Adult
Aged
Antineoplastic Agents
/ therapeutic use
Biomarkers
/ blood
Brain-Derived Neurotrophic Factor
/ blood
Breast Neoplasms
/ complications
Cognitive Dysfunction
/ prevention & control
Depression
/ drug therapy
Double-Blind Method
Female
Humans
Melatonin
/ pharmacology
Membrane Glycoproteins
/ blood
Middle Aged
Neuropsychological Tests
Placebo Effect
Receptor, trkB
/ blood
Sleep
/ drug effects
Treatment Outcome
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
06
08
2019
accepted:
22
03
2020
entrez:
18
4
2020
pubmed:
18
4
2020
medline:
9
7
2020
Statut:
epublish
Résumé
This randomized, double-blinded, placebo-controlled trial tested the hypothesis that 20mg of melatonin before and during the first cycle of adjuvant chemotherapy for breast cancer (ACBC) reduced the side effects associated with cognitive impairment. We evaluated the effects of melatonin on cognition, depressive symptoms and sleep quality, and whether these effects were related to serum levels of Brain Derived Neurotrophic Factor (BDNF) and its receptor, tropomyosin kinase B (TrkB). Thirty-six women were randomly assigned to receive melatonin or placebo for 10 days. To evaluate cognitive performance, we used the Trail-Making-Test Parts A and B (A-B), Rey Auditory-Verbal Learning Test (RAVLT), Controlled Oral Word Association Test (COWAT) and an inhibitory task type Go / No-Go. Our results revealed that melatonin improved executive function on TMT scores, enhanced episodic memory (immediate and delayed) and recognition on RAVLT, and increased verbal fluency in the orthographic COWAT. The TMT-A-B(A-B) were negatively correlated with baseline levels of TrkB and BDNF, respectively. At the end of treatment, changes in TrkB and BDNF were inversely associated with depressive symptoms and sleep quality, but not with the TMT scores. These results suggest a neuroprotective effect of melatonin to counteract the adverse effects of ACBC on cognitive function, sleep quality and depressive symptoms.
Identifiants
pubmed: 32302347
doi: 10.1371/journal.pone.0231379
pii: PONE-D-19-21207
pmc: PMC7164654
doi:
Substances chimiques
Antineoplastic Agents
0
Biomarkers
0
Brain-Derived Neurotrophic Factor
0
Membrane Glycoproteins
0
BDNF protein, human
7171WSG8A2
Receptor, trkB
EC 2.7.10.1
tropomyosin-related kinase-B, human
EC 2.7.10.1
Melatonin
JL5DK93RCL
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0231379Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Biol Psychiatry. 2018 Jan 1;83(1):5-6
pubmed: 29173706
Biochim Biophys Acta Mol Basis Dis. 2019 Jun 1;1865(6):1088-1097
pubmed: 30759363
Curr Neuropharmacol. 2016;14(7):721-31
pubmed: 26786147
Wien Med Wochenschr. 2019 Feb;169(1-2):33-40
pubmed: 30232660
J Clin Sleep Med. 2009 Feb 15;5(1):41-51
pubmed: 19317380
Braz J Psychiatry. 2007 Dec;29(4):324-9
pubmed: 17713697
Cancer Nurs. 2014 May-Jun;37(3):E31-42
pubmed: 23945143
Int J Cancer. 2016 Dec 15;139(12):2635-2645
pubmed: 27367824
Mol Pain. 2014 Jul 08;10:46
pubmed: 25005881
Braz J Psychiatry. 2013 Oct-Dec;35(4):416-31
pubmed: 24402217
Pain. 2013 Jun;154(6):874-81
pubmed: 23602498
Breast Cancer Res Treat. 2014 Jun;145(2):381-8
pubmed: 24718775
Br J Pharmacol. 2018 Aug;175(16):3190-3199
pubmed: 29318587
Br J Pharmacol. 2018 Aug;175(16):3200-3208
pubmed: 29512136
Front Cell Neurosci. 2014 Dec 22;8:430
pubmed: 25565964
Pathol Biol (Paris). 2007 Apr-May;55(3-4):201-4
pubmed: 17446010
Breast Cancer Res Treat. 2013 Jan;137(1):33-43
pubmed: 23053652
Cochrane Database Syst Rev. 2012 Nov 14;11:MR000030
pubmed: 23152285
J Clin Oncol. 2012 Oct 20;30(30):3675-86
pubmed: 23008308
Anesth Analg. 2005 Mar;100(3):795-802, table of contents
pubmed: 15728070
J Clin Oncol. 2012 Oct 10;30(29):3578-87
pubmed: 22927526
Cancer Chemother Pharmacol. 2012 May;69(5):1213-20
pubmed: 22271210
Chronobiol Int. 2013 Nov;30(9):1077-88
pubmed: 23879696
Prog Neurobiol. 2008 Jul;85(3):335-53
pubmed: 18571301
Immunol Invest. 2019 Aug;48(6):632-643
pubmed: 30887869
Behav Brain Res. 2013 Nov 1;256:72-81
pubmed: 23933144
Intelligence. 2011 Jul;39(4):222-232
pubmed: 21789028
PLoS One. 2014 Sep 26;9(9):e108002
pubmed: 25259847
Chin Med J (Engl). 2014;127(15):2808-13
pubmed: 25146619
Crit Rev Food Sci Nutr. 2019;59(sup1):S4-S16
pubmed: 29902071
Integr Cancer Ther. 2012 Dec;11(4):293-303
pubmed: 22019490
J Cell Biochem. 2017 Sep;118(9):2502-2515
pubmed: 28230291
Brain Behav Immun. 2007 Mar;21(3):251-8
pubmed: 17008048
Inflammation. 2018 Mar;41(2):515-529
pubmed: 29198013
Integr Cancer Ther. 2009 Dec;8(4):337-46
pubmed: 20050373
Support Care Cancer. 2016 Mar;24(3):1097-105
pubmed: 26260726
Nat Rev Clin Oncol. 2016 Feb;13(2):92-105
pubmed: 26391778
J Biol Chem. 2015 Feb 6;290(6):3814-24
pubmed: 25538243
Ann Oncol. 2015 Jul;26(7):1446-51
pubmed: 25922060
Sleep Med. 2019 Mar;55:14-21
pubmed: 30743205
Scand J Work Environ Health. 1984;10 Suppl 1:25-9
pubmed: 6494852
Neurosci Lett. 2003 May 29;343(1):1-4
pubmed: 12749983
Expert Opin Investig Drugs. 2012 Jun;21(6):819-31
pubmed: 22500582
Support Care Cancer. 2019 Aug;27(8):3035-3043
pubmed: 30610433
Cancer. 2015 Oct 15;121(20):3727-36
pubmed: 26178160
Support Care Cancer. 2012 Feb;20(2):319-24
pubmed: 21243377
Appl Prev Psychol. 2007 Dec;12(3):99-114
pubmed: 19050749
Proc Natl Acad Sci U S A. 1999 Jul 6;96(14):8301-6
pubmed: 10393989
Eur J Cancer Care (Engl). 2015 Jul;24(4):553-9
pubmed: 25727241
Clin Cancer Res. 2006 May 1;12(9):2759-66
pubmed: 16675568
Nat Rev Neurosci. 2008 Jan;9(1):46-56
pubmed: 18073775
Front Hum Neurosci. 2017 Jun 20;11:316
pubmed: 28676747
J Pineal Res. 1998 Oct;25(3):177-83
pubmed: 9745987
J Pineal Res. 2019 Jan;66(1):e12538
pubmed: 30415481
Anticancer Res. 2014 Dec;34(12):7327-37
pubmed: 25503168
Front Psychol. 2014 Jul 22;5:772
pubmed: 25101034
Front Endocrinol (Lausanne). 2019 Jul 16;10:391
pubmed: 31379733
Eur Neuropsychopharmacol. 2006 Oct;16(7):538-45
pubmed: 16527463
Int J Breast Cancer. 2014;2014:416531
pubmed: 25328711
Sci Rep. 2018 Jul 3;8(1):10054
pubmed: 29968776
J Int Neuropsychol Soc. 2005 May;11(3):290-302
pubmed: 15892905
J Pineal Res. 2019 Mar;66(2):e12545
pubmed: 30586198
J Neurosci. 2012 Jun 27;32(26):8988-99
pubmed: 22745498
Neuropsychobiology. 2017;76(3):117-129
pubmed: 29898451
Expert Opin Ther Targets. 2015 Apr;19(4):565-76
pubmed: 25519921
Mol Psychiatry. 2018 Jul;23(7):1575-1583
pubmed: 28924184
Oncologist. 2008 Dec;13(12):1285-95
pubmed: 19019972
Ann N Y Acad Sci. 2000;917:560-7
pubmed: 11268384
Lancet Oncol. 2011 Jul;12(7):703-8
pubmed: 21354373
Oncologist. 2011;16(12):1741-51
pubmed: 22101506